Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review

Authors Suzanne A Ligthart, Eric P Moll van Charante, Willem A Van Gool, et al

Published 17 August 2010 Volume 2010:6 Pages 775—785

DOI http://dx.doi.org/10.2147/VHRM.S7343

Review by Single-blind

Peer reviewer comments 3

Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, ­hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension

Shuster JE, Bleske BE, Dorsch MP

Vascular Health and Risk Management 2012, 8:381-387

Published Date: 13 June 2012

Hypothyroidism and the risk of lower extremity arterial disease

Michael A Mazzeffi, Hung-Mo Lin, Brigid C Flynn, et al

Vascular Health and Risk Management 2010, 6:957-962

Published Date: 20 October 2010

Impact of a diabetic foot care education program on lower limb amputation rate

Abdullah M Al-Wahbi

Vascular Health and Risk Management 2010, 6:923-934

Published Date: 11 October 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Estimating glomerular filtration rate in a population-based study

Anoop Shankar, Kristine E Lee, Barbara EK Klein, et al

Vascular Health and Risk Management 2010, 6:619-627

Published Date: 16 July 2010

New options with dabigatran etexilate in anticoagulant therapy

Lars Maegdefessel, Joshua M Spin, Junya Azuma, et al

Vascular Health and Risk Management 2010, 6:339-349

Published Date: 10 May 2010

Recent achievements in the management of Raynaud’s phenomenon

Magnus Baumhäkel, Michael Böhm

Vascular Health and Risk Management 2010, 6:207-214

Published Date: 30 March 2010

Computerized assessment of pain drawing area: A pilot study

Anna Wenngren, Britt-Marie Stålnacke

Neuropsychiatric Disease and Treatment 2009, 5:451-456

Published Date: 20 August 2009

Emerging treatments for premature ejaculation: focus on dapoxetine

Wayne JG Hellstrom

Neuropsychiatric Disease and Treatment 2009, 5:37-46

Published Date: 21 December 2008